CA2356189A1 - Substance for obtaining highly effective tumor medications as well as a process - Google Patents
Substance for obtaining highly effective tumor medications as well as a process Download PDFInfo
- Publication number
- CA2356189A1 CA2356189A1 CA002356189A CA2356189A CA2356189A1 CA 2356189 A1 CA2356189 A1 CA 2356189A1 CA 002356189 A CA002356189 A CA 002356189A CA 2356189 A CA2356189 A CA 2356189A CA 2356189 A1 CA2356189 A1 CA 2356189A1
- Authority
- CA
- Canada
- Prior art keywords
- glycoprotein
- substances
- substance
- tumor
- bind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a substance and a method for producing anti-tumour agents. This substance corresponds to a fragment of the glycoprotein CD55/DAF
and can also be used for diagnostic purposes.
and can also be used for diagnostic purposes.
Claims (29)
1. Glycoprotein that comprises at least one section of the amino acid primary structure of CD55 and a tumor-specific glycostructure.
2. Glycoprotein according to claim 1, characterized in that the glycostructure reacts with monoclonal antibody SC-1.
3. Glycoprotein according to claim 1 or 2, wherein in SDS-polyacrylamide-gel electrophoresis, it exhibits an apparent molecular weight of 82 kD.
4. Process for obtaining a glycoprotein according to one of claims 1 to 3, wherein membrane preparations are produced from cells of the human adenocarcinoma cell line 23132, and the glycoprotein is obtained therefrom by size-exclusion and/or anion-exchange chromatography.
5. Use of a glycoprotein according to one of claims 1 to 3 in a test process in which the ability of a substance to bind to the glycoprotein is determined.
6. Use according to claim 5, wherein the ability to bind to the glycostructure is determined.
7. Use according to claim 5 or 6, wherein the ability of the tested substance to induce apoptosis, especially in tumor cells, is determined.
8. Use according to one of claims 5 to 7, wherein the ability of the tested substance to induce a phosphorylation cascade that is mediated by glycoprotein CD55 is determined.
9. Use according to claims 5 to 8, wherein the glycoprotein is used in isolated form, as a cell extract, especially as a membrane preparation or in the form of complete cells, especially of human adenocarcinoma cell line 23132.
10. Use according to one of claims 5 to 9 for identifying substances that bind specifically to tumor cells.
11. Use according to claim 10 for identifying agents for tumor diagnosis and/or tumor therapy.
12. Use according to one of claims 5 to 11, wherein the pharmacologically compatible substances are tested.
13. Use according to claim 12, wherein the tested substances are selected from peptides, peptide mimetic agents, antibodies, antibody fragments and antibody derivatives.
14. Use of substances that bind specifically to a glycoprotein according to one of claims 1 to 3, with the exception of the monoclonal antibody SC-1, for the production of agents that induce apoptosis.
15. Use of substances that bind specifically to a glycoprotein according to one of claims 1 to 3, with the exception of monoclonal antibody SC-1, for the production of anti-tumor agents.
16. Use of substances that bind specifically to a glycoprotein according to one of claims 1 to 3, with the exception of monoclonal antibody SC-1, for the production of agents for tumor diagnosis.
17. Process for the preparation of the agents that induce apoptosis, wherein a potentially active substance is tested on its ability for specific binding to a glycoprotein according to one of claims 1 to 3 and in the case of a positive test result, the substance is converted into a form for dispensing that is suitable for pharmaceutical applications optionally together with commonly used adjuvants, additives and vehicles.
18. Process for the preparation of anti-tumor agents, wherein a potentially active substance is tested on its ability for specific binding to a glycoprotein according to one of claims 1 to 3 and in the case of a positive test result, the substance is converted into a form for dispensing that is suitable for pharmaceutical applications optionally together with commonly used adjuvants, additives and vehicles.
19. Process for combatting tumors, wherein an anti-tumor-action quantity of a substance that can bind specifically to a glycoprotein according to one of claims 1 to 3, with the exception of monoclonal antibody SC-1, is administered to a patient.
20. Process for diagnosis of tumors, wherein a sample that is to be tested or a patient who is to be tested is brought into contact with a substance that can bind specifically to a glycoprotein according to one of claims 1 to 3, and the presence, the localization and/or the quantity of the glycoprotein in the sample or in the patient is detected.
21. Use of substances that specifically bind a glycoprotein according to one of claims 1 to 3 to trigger a phosphorylation cascade in tumor cells.
22. Use of substances that bind specifically to a glycoprotein according to one of claims 1 to 3 for transient increase of the CD55/DAF presentation in membranes of tumor cells.
23. Use of substances that specifically bind a glycoprotein according to one of claims 1 to 3 for inducing apoptotic processes that do not comprise any cleavage of poly(ADP-ribose)-polymerase (PARP).
24. Use of substances that specifically bind a glycoprotein according to one of claims 1 to 3 for inducing a cell cycle arrest in tumor cells.
25. Use of substances that bind specifically to a glycoprotein according to one of claims 1 to 3 for inducing apoptosis in dormant tumor cells.
26. Use according to one of claims 21 to 25, wherein the specifically bindable substance comprises antibody SC-1.
27. Use according to one of claims 21 to 26, wherein the substances are used in the form of conjugates with labeling or effector groups.
28. Use according to one of claims 21 to 27, wherein the substances have multiple binding sites for a glycoprotein according to one of claims 1 to 3.
29. Use according to claim 28, wherein the specifically bindable substances are cross-linked.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19859248 | 1998-12-22 | ||
| DE19859248.5 | 1998-12-22 | ||
| DE19909771.2 | 1999-03-05 | ||
| DE19909771A DE19909771A1 (en) | 1998-12-22 | 1999-03-05 | Substance for the production of highly effective tumor drugs and methods |
| PCT/EP1999/010329 WO2000037489A2 (en) | 1998-12-22 | 1999-12-22 | Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2356189A1 true CA2356189A1 (en) | 2000-06-29 |
| CA2356189C CA2356189C (en) | 2010-08-24 |
Family
ID=26050926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2356189A Expired - Fee Related CA2356189C (en) | 1998-12-22 | 1999-12-22 | Substance for obtaining highly effective tumor medications as well as a process |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1141019B1 (en) |
| AT (1) | ATE264873T1 (en) |
| AU (2) | AU772579B2 (en) |
| CA (1) | CA2356189C (en) |
| DK (1) | DK1141019T3 (en) |
| ES (1) | ES2219108T3 (en) |
| PT (1) | PT1141019E (en) |
| WO (1) | WO2000037489A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2004105599A (en) | 2001-07-24 | 2005-07-27 | Онкомаб Гмбх (De) | RECEPTOR, ITS APPLICATION AND MOUSE ANTIBODY |
| WO2004005351A2 (en) | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
| GB0227644D0 (en) * | 2002-11-27 | 2003-01-08 | Cancer Rec Tech Ltd | Specific binding members and uses thereof |
| DE10311248A1 (en) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody |
| EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
| DE10353175A1 (en) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody with fatliquoring effect |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| GB9804065D0 (en) * | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Tumour associated antigen 791Tgp72 |
-
1999
- 1999-12-22 AT AT99969227T patent/ATE264873T1/en active
- 1999-12-22 PT PT99969227T patent/PT1141019E/en unknown
- 1999-12-22 DK DK99969227T patent/DK1141019T3/en active
- 1999-12-22 CA CA2356189A patent/CA2356189C/en not_active Expired - Fee Related
- 1999-12-22 ES ES99969227T patent/ES2219108T3/en not_active Expired - Lifetime
- 1999-12-22 AU AU27955/00A patent/AU772579B2/en not_active Ceased
- 1999-12-22 WO PCT/EP1999/010329 patent/WO2000037489A2/en active IP Right Grant
- 1999-12-22 EP EP99969227A patent/EP1141019B1/en not_active Expired - Lifetime
-
2004
- 2004-07-29 AU AU2004203479A patent/AU2004203479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000037489A3 (en) | 2000-11-09 |
| EP1141019B1 (en) | 2004-04-21 |
| EP1141019A2 (en) | 2001-10-10 |
| AU2004203479A1 (en) | 2004-08-26 |
| DK1141019T3 (en) | 2004-08-09 |
| CA2356189C (en) | 2010-08-24 |
| AU772579B2 (en) | 2004-04-29 |
| PT1141019E (en) | 2004-09-30 |
| ATE264873T1 (en) | 2004-05-15 |
| WO2000037489A2 (en) | 2000-06-29 |
| AU2795500A (en) | 2000-07-12 |
| ES2219108T3 (en) | 2004-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anderson et al. | Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide | |
| Tschopp et al. | Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. | |
| Cai et al. | Self‐adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T‐cell epitopes from tetanus toxoid | |
| Nores et al. | Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. | |
| Collatz et al. | Further investigations of circulating antibodies in colon cancer patients: on the autoantigenicity of the carcinoembryonic antigen | |
| US9796777B2 (en) | Methods of treating malignant tumors | |
| KR20190133010A (en) | Personalized Immunogenic Peptide Identification Platform | |
| Banjo et al. | Intermolecular heterogeneity of the carcinoembryonic antigen | |
| JP2004515202A5 (en) | ||
| JP2016531583A (en) | Immune system modulator | |
| BR9808863A (en) | Peptide antiestrogenic compositions and methods to treat breast cancer | |
| Nakajima et al. | Relationship between human IgE-binding factors (IgE-BF) and lymphocyte receptors for IgE. | |
| WO1993012145A1 (en) | Pva or peg conjugates of peptides for epitope-specific immunosuppression | |
| Klip et al. | Alignment of the major tryptic fragments of the adenosine triphosphatase from sarcoplasmic reticulum. | |
| CN111138521B (en) | Short peptides derived from AFP antigen | |
| CA2356189A1 (en) | Substance for obtaining highly effective tumor medications as well as a process | |
| US5780298A (en) | DNA encoding the sn-RNP-A antigen and fragments thereof | |
| Davie et al. | Chemical characterization of glycopeptides from human γM-globulins | |
| Hefta et al. | Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry. | |
| Blackburn et al. | Principal polypeptide target of carcinogen at the beginning of liver carcinogenesis by three carcinogens | |
| Stein et al. | Induction of anti-mistletoe lectin antibodies in relation to different mistletoe extracts | |
| JPH07508749A (en) | Antigenic regions of tumor-released particle (TLP) complexes and antibodies against them | |
| Pellis et al. | Use of preparative isoelectric focusing in a Sephadex gel slab to separate immunizing and growth facilitating moieties in crude 3 M KCl extracts of a murine fibrosarcoma | |
| Gold et al. | Antigens associated with human solid tumors | |
| de Tribolet et al. | Human glioma tumour-associated antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161222 |